SynthesisBrain and behavior2026
Advancements in Glioblastoma Multiforme Treatment: A Comprehensive Systematic Review and Meta-Analysis.
Synthesis in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioblastoma multiforme (GBM) poses significant challenges in oncology, with limited treatment options and poor prognosis. Despite advancements, recurrence remains common, emphasizing the need for effective therapeutic strategies. This meta-analysis comprehensively evaluates the efficacy and safety of treatments like bevacizumab (BEV), temozolomide (TMZ), and lomustine (CCNU) for recurrent GBM (rGBM), aiming to identify optimal approaches and guide clinical decisions.
methodsFollowing Preferred Reporting Standards for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a systematic review was conducted, and randomized controlled trials assessing interventions for rGBM were included. The Cochrane risk-of-bias assessment was used to evaluate study quality. Primary outcomes included progression-free survival (PFS) and overall survival (OS), whereas adverse events were assessed as secondary outcomes.
resultsNine articles met the inclusion criteria, comprising a total of 1689 participants. BEV therapy outperformed pre-BEV treatment across several parameters, including full resection (odds ratio [OR] = 14.50, 95% confidence intervals [CI]: 1.82-115.29, p = 0.01) and biopsy outcomes (OR = 18.67, 95% CI: 2.55-136.41, p = 0.04). BEV also demonstrated higher rates of MGMT promoter methylation at baseline (OR = 11.84, 95% CI: 1.87-74.77, p = 0.009), as well as associations with improved PFS (OR = 1.16, 95% CI: 0.10-2.22, p = 0.03) and OS (OR = 0.63, 95% CI: 0.01-1.26, p = 0.05) compared to pre-BEV therapies. BEV monotherapy was associated with more favorable outcomes than combination therapies, with a pooled OR of 19.50 (95% CI: 2.69-141.35, p = 0.03) for corticosteroid use. Adverse event analysis revealed a lower incidence of CNS hemorrhage with standard therapy. TMZ outperformed the TMZ + CCNU combination in PFS (OR = 2.44, 95% CI: 1.23-4.83, p = 0.01), OS, and MGMT methylation (OR = 2.58, 95% CI: 1.40-4.78, p = 0.002).
conclusionBEV monotherapy emerges as a promising treatment for rGBM, with favorable outcomes in biopsy results, corticosteroid use, PFS, and OS. Future research is needed to confirm these findings and optimize BEV's clinical application, emphasizing tailored treatment strategies to improve patient prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.